Q3 FY26 results: Revenue up 7%, PAT down 39% YoY on standalone

Emphasis of matterExceptional itemResults View source PDF Explain this filing

NEOGEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.7%Reaction day

₹1295.00

prior close

₹1275.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.5%-0.2% vs market

Specialty Chemicals peers, median of 86sector-0.8%+0.1% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.1 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.2

10m

-1.0

15m

-1.2

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.7-0.5-0.2-0.8+0.1

Next day

-1.7-2.0+0.3-2.0+0.3

-1.1-2.7+1.5-3.4+2.3

+0.4-1.7+2.1-3.1+3.5

+2.3-1.4+3.8-2.9+5.2

+3.9-2.8+6.7-3.6+7.5

+7.0-2.8+9.9-4.3+11.3

15d

+2.4-8.4+10.8-10.2+12.5

+11.7-9.1+20.8-9.6+21.3

+6.5-4.0+10.5-6.5+13.0

+26.6+2.6+24.0+1.5+25.1

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 86Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Neogen Chemicals posted Q3 FY26 standalone revenue of Rs. 215.60 cr, up 7.6% YoY. However, PAT fell 39% to Rs. 8.77 cr due to higher costs and finance expenses. For 9M FY26, revenue grew 6.5% to Rs. 606.86 cr while PAT dropped 25% to Rs. 32.30 cr. Consolidated 9M PAT fell 47% to Rs. 17.33 cr. Auditor flagged an emphasis of matter on the March 2025 Dahej fire; company has received Rs. 83.48 cr from insurance so far. Long term rating stands at Crisil A/Negative.

Likely market impact

Revenue growth steady but profits under pressure from rising costs and finance charges. Insurance recovery progress remains a key watchpoint.